Are Peptides Legal? The U.S. Status in 2026

“Is it legal?” is the most common question about peptides, and it has no single answer. “Peptide” is a chemistry category, not a legal one. Whether a given peptide is lawful to sell, possess, or use depends on three things: which specific molecule it is, what it is being sold or used for, and who is doing the selling, compounding, or possessing. Three separate systems govern these substances, and they are constantly confused for one another. This page is a reference, not legal advice.

Three systems that get conflated

Most confusion about peptide legality comes from blending three independent regimes that each answer a different question.

The FDA, under the Food, Drug, and Cosmetic Act, decides whether something is an approved drug, an unapproved new drug, or eligible for pharmacy compounding. This is where most peptide “illegality” actually lives.
The DEA, under the Controlled Substances Act, decides scheduling. Most peptides are not scheduled, and that fact is widely misread as “legal.”
WADA, the world anti-doping system, governs athletes. It is a contractual regime, not a law, but for competitors it is decisive.

The single most important correction: “not a controlled substance” does not mean “legal to sell for human use.” A peptide can be entirely unscheduled by the DEA and still be an unapproved new drug that is unlawful to market for people. These are different laws answering different questions.

Approved peptide drugs versus “research use only”

Some peptides are FDA-approved drugs and are unambiguously legal when prescribed and used as labeled. Insulin has been approved for a century. Modern examples include the GLP-1 and GIP medicines: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda). The exact count of approved peptide products depends on how you define “peptide”; one curated database (THPdb2) catalogs roughly 85 approved peptides and polypeptides, so “around 80-plus” is a fair approximation rather than an official FDA tally.

By contrast, the peptides sold online as “research use only” (RUO) — BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, MOTS-c, epitalon, semax, and others — are generally unapproved new drugs. Labeling a vial “not for human consumption” or “for laboratory research purposes only” does not make it legal if the seller actually intends people to use it. The FDA applies an “intended use” doctrine: it looks past the disclaimer to the totality of the evidence — website claims, testimonials, dosing language, and details like selling injectable peptides alongside bacteriostatic water and syringes. Standard FDA warning-letter language treats products labeled “for laboratory research purposes only” and “not for human consumption” as intended-for-human drugs whenever the marketing establishes that intent.

The agency has acted on this repeatedly. Warning letters to USA Peptide (February 2025), Summit Research Peptides (December 2024), and Gram Peptides (March 2026) all cite RUO labeling paired with marketing — weight-loss claims, dosing, accessories — that established human-use intent. We cover the disclaimer in more depth in Research Use Only, Explained and the broader supply picture in The Gray Market.

Selling versus possessing

The federal line falls hardest on commerce. Selling, distributing, or marketing an unapproved peptide for human use violates the FD&C Act as an unapproved or misbranded new drug, and this is where FDA enforcement concentrates: warning letters, seizures, injunctions, and criminal charges in egregious cases.

Mere personal possession of a non-controlled peptide is generally not itself a federal crime under the FD&C Act, because the Act targets the commercial chain — manufacturing, distributing, and introducing products into interstate commerce. That is a narrow technical point, not a green light: it does not mean the substance is safe, that its use is sanctioned, that it can be lawfully imported (the FDA can refuse or detain imports), or that state law allows it.

One peptide carries a far harsher, dedicated regime. Under 21 U.S.C. § 333(e), knowingly distributing human growth hormone — or possessing it with intent to distribute — for any use in humans other than treatment of a disease or recognized medical condition authorized by HHS and ordered by a physician is a federal crime punishable by up to 5 years (up to 10 if distributed to someone under 18). hGH is federally unscheduled, yet this statute makes off-label distribution a serious offense in its own right.

Pharmacy compounding: the heart of the 2026 story

Compounding pharmacies (operating under section 503A, filling patient-specific prescriptions) and outsourcing facilities (under 503B) may compound from a bulk drug substance only if it has an applicable USP monograph, is a component of an FDA-approved drug, or appears on the FDA’s developed “503A bulks list.” For substances not yet adjudicated, the FDA’s Interim Policy sorts them into categories: Category 1 substances are treated with enforcement discretion (compounding tolerated pending rulemaking), while Category 2 substances pose “significant safety risks” and the FDA will not exercise discretion — effectively prohibiting their compounding.

In September 2023, the FDA placed BPC-157 and a group of popular peptides into Category 2, citing immunogenicity risk, peptide-related manufacturing impurities, and limited human safety data.

Then came a major shift. On April 15–16, 2026, through an update to its 503A bulk-substances list and a Federal Register notice, the FDA announced it was removing 12 peptides from Category 2 and convening its Pharmacy Compounding Advisory Committee (PCAC). This is the most misreported development of the year, so it is worth stating plainly: removal from Category 2 does not place these peptides on the bulks list, does not make them Category 1, and does not authorize compounding. They now sit in a regulatory gray zone pending committee review and, if recommended, full notice-and-comment rulemaking — a process that can take more than a year.

The committee’s first meeting is scheduled for July 23–24, 2026 at FDA White Oak, reviewing seven peptides: BPC-157, KPV, TB-500, and MOTS-c on July 23, and emideltide (DSIP), semax, and epitalon on July 24. A second meeting, expected before the end of February 2027, will cover the remaining five: GHK-Cu, melanotan II, cathelicidin (LL-37), dihexa acetate, and PEG-MGF. As reporting (not legal fact), the reconsideration follows HHS Secretary Robert F. Kennedy Jr.’s stated push for broader peptide access, which he described publicly in early 2026. Supporters of the move argue the original Category 2 placement swept in compounds of genuine clinical interest on thin evidence and that a fresh look is overdue; critics such as Public Citizen warn it lowers the safety bar. The disagreement is the useful part: these classifications are contested policy calls that shift with the people making them, not settled science — a compound’s regulatory tier in 2026 says more about where the rulemaking stands than about what the molecule does.

The practical takeaway: as of June 2026, BPC-157 and the other reviewed peptides are not legally compoundable. Their status is “under active FDA reconsideration,” with the outcome and timing uncertain.

The GLP-1 compounding situation

Compounding of an FDA-approved drug is generally barred unless that drug is on the FDA’s shortage list. The GLP-1 compounding boom rode exactly that exception, and it has now closed. The FDA reaffirmed tirzepatide’s shortage resolution on December 19, 2024, with stop-compounding deadlines of February 18, 2025 (503A) and March 19, 2025 (503B). Semaglutide came off the shortage list on February 21, 2025, with deadlines of April 22 and May 22, 2025.

In 2026 the FDA went further. On April 30, 2026 (Federal Register notice published May 1), it proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no “clinical need” — a move that would permanently bar large-scale outsourcing-facility compounding from bulk. The comment period closes June 30, 2026.

One nuance: limited, patient-specific 503A compounding of a commercially available drug can still be lawful where there is a documented clinical difference for an individual — for example, a genuine allergy to an inactive ingredient. What is no longer shielded is routine mass production of “compounded semaglutide.” And “research use only” semaglutide or tirzepatide powder sold online is a separate problem entirely: that is an unapproved drug, not compounding.

DEA scheduling

Most peptides are not controlled substances. BPC-157, TB-500, GHK-Cu, the GLP-1 agonists, and growth-hormone secretagogues like ipamorelin are not scheduled under the CSA. This is the trap worth repeating: being unscheduled is not a license to sell for human use, because FDA unapproved-drug law still applies. The notable exception is human growth hormone, controlled not by CSA scheduling but by the dedicated criminal statute discussed above. Before relying on any specific compound’s scheduling status, check the official DEA schedules directly rather than a vendor’s summary.

Athletes: WADA bans most peptides outright

For athletes under WADA-compliant bodies, peptide status is set by the 2026 Prohibited List (in force January 1, 2026), entirely independent of FDA or DEA status. Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — is prohibited at all times, in and out of competition, with strict liability. It covers EPO and related agents, growth hormone and its fragments and releasing factors, growth-hormone secretagogues (named examples include ibutamoren/MK-677, ipamorelin, the GHRPs, hexarelin, and others), and growth factors such as IGF-1, MGF, VEGF, PDGF, FGF, and TB-500.

BPC-157 is not explicitly named on the 2026 list, but it is caught by the catch-all language for substances with similar structure or biological effect under S2, and by the non-approved-substance catch-all (S0). Either way it is prohibited at all times. By contrast, the GLP-1 agonists semaglutide and tirzepatide are not banned under WADA 2026 — they sit on the Monitoring Program (semaglutide added in 2024, tirzepatide in 2026), which surprises many people. For a fuller treatment, see Peptides and Anti-Doping.

Bottom line

There is no blanket answer to “are peptides legal.” Approved peptide drugs are legal when prescribed and used as labeled. The “research use only” peptides sold online are generally unapproved new drugs, and the RUO label does not cure unlawful human-use intent. Selling for human use is the main federal violation; personal possession of a non-controlled peptide is a gray area but not FDA-blessed, and hGH carries its own criminal statute. Compounding hinges on the 503A/503B framework — and although the FDA removed 12 peptides from Category 2 in April 2026, none of them are legally compoundable yet, with committee reviews running into 2027. Most peptides are not DEA-scheduled, but that is not permission to sell them for people. And for athletes, the S2 peptides are banned at all times. If you are weighing any of this, verify the current status of the specific molecule against primary sources, because this area is changing month to month. When you read claims about safety or quality, our guides on how to read a certificate of analysis and independent testing explain why a legal-status label tells you nothing about what is in a vial.